This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Research reveals the role of TonEBP in lupus and lupus nephritis, opening new avenues for treatment

Research reveals the role of TonEBP in lupus and lupus nephritis, opening new avenues for treatment
TonEBP expression in endothelial cells, epithelial cells, and infiltrating immune cells in renal biopsy tissues subjected to multiplex immune fluorescence staining. Biopsy sections were double stained for TonEBP (red) and cell surface markers (green): CD31, cytokeratin (CK), CD4, CD8, CD68, or CD86. Nuclei were visualized with 4′,6-diamidino-2-phenylindole (DAPI; blue). Representative pseudocolor merged images of the renal cortex and medulla are shown for both controls and the patients with lupus nephritis (LN). Merged image demonstrates colocalization of TonEBP and DAPI in the nucleus (purple) and cell markers on the cell surface and cytoplasm (green). Original magnification ×200 (bars = 100 μm) and ×400 (boxed areas; bars = 20 μm). G, glomerulus. Credit: Ulsan National Institute of Science and Technology

An important discovery has been made by Professor Hyug Moo Kwon and his research team in the Department of Biological Sciences at UNIST, in collaboration with Professor Jaeseok Yang from Yonsei University. Their study sheds new light on the protein called 'TonEBP,' revealing its significant role in the development of lupus and lupus nephritis. This breakthrough not only enhances our understanding of these conditions, but also opens up potential avenues for future treatment options.

Lupus is an autoimmune disorder characterized by autoreactive B cells and dysregulation of various immune cells, including myeloid cells. Lupus nephritis (LN), which refers to kidney inflammation caused by lupus, is one of the most common organ manifestations associated with (SLE). The study conducted meticulous analysis on kidney biopsy samples obtained from LN patients to investigate TonEBP's involvement in these conditions.

The findings unveiled elevated expression levels of TonEBP not only within kidney cells but also infiltrating immune cells when compared to control patients. This increased expression correlated with involved in inflammatory reactions triggered by bacterial or , as well as severity of proteinuria—a key indicator reflecting .

To delve deeper into TonEBP's impact on both lupus development and kidney damage, were conducted. The results demonstrated that specifically suppressing TonEBP within myeloid cells effectively halted lupus progression while mitigating kidney damage.

Additionally, animal models with myeloid deficiency of TonEBP exhibited elevated efferocytosis (phagocytic clearance) alongside reduced differentiation of Th1 (T helper 1) and Th17 (T helper 17) cells—indicating impaired Toll-like receptor (TLR) signaling, which is crucial for T cell function.

Furthermore, the study revealed that various TLRs stimulated macrophages to induce TonEBP expression through promoter activation—a critical intracellular signaling pathway dependent on TonEBP. This finding suggests that TonEBP acts as a transcriptional cofactor for NF-κB and activates mTOR-IRF3/7 via protein-protein interactions.

"This study unveils the pivotal role of TonEBP in lupus development," stated Professor Kwon. "By identifying the underlying cause and providing valuable clues for new treatments, we aim to contribute to improving the lives of individuals affected by these conditions."

The research findings were made available in Kidney International.

More information: Eun Jin Yoo et al, Macrophage transcription factor TonEBP promotes systemic lupus erythematosus and kidney injury via damage-induced signaling pathways, Kidney International (2023). DOI: 10.1016/j.kint.2023.03.030

Journal information: Kidney International
Citation: Research reveals the role of TonEBP in lupus and lupus nephritis, opening new avenues for treatment (2023, September 12) retrieved 21 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Hepatocellular carcinoma diagnosis, prognosis and treatment may improve by identifying a protein


Feedback to editors